文献
(101～200)101. Kittleson MM, Bead V, Fradley M, et al. Elevated uric acid levels predict allograft vasculopathy in cardiac transplant recipients. J Heart
Lung Transplant 2007; 26: 498-503. PMID: 17449420
102. Hamaguchi S, Furumoto T, Tsuchihashi-Makaya M, et al. JCARECARD Investigators. Hyperuricemia predicts adverse outcomes in
patients with heart failure. Int J Cardiol 2011; 151: 143-147. PMID:20542341
103. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic
peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol 2008; 52: 266-272.
PMID: 18634981
104. Kistorp C, Faber J, Galatius S, et al. Plasma adiponectin, body mass index, and mortality in patients with chronic heart failure. Circulation
2005; 112: 1756-1762. PMID: 16157772
105. George J, Patal S, Wexler D, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart 2006; 92: 1420-
1424. PMID: 16621874
106. Tsutamoto T, Tanaka T, Sakai H, et al. Total and high molecular weight adiponectin, haemodynamics, and mortality in patients with
chronic heart failure. Eur Heart J 2007; 28: 1723-1730. PMID:17507366
107. Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;
332: 411-415. PMID: 2451132
108. Tsutamoto T, Hisanaga T, Fukai D, et al. Prognostic value of plasma soluble intercellular adhesion molecule-1 and endothelin-1
concentration in patients with chronic congestive heart failure. Am J Cardiol 1995; 76: 803-808. PMID: 7572659
109. Van Beneden R, Gurné O, Selvais PL, et al. Superiority of big endothelin- 1 and endothelin-1 over natriuretic peptides in predicting survival
in severe congestive heart failure: a 7-year follow-up study. J Card Fail 2004; 10: 490-495. PMID: 15599839
110. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive
heart failure. Circulation 2000; 101: 498-503. PMID: 10662746
111. Mahdyoon H, Klein R, Eyler W, et al. Radiographic pulmonary congestion in end-stage congestive heart failure. Am J Cardiol 1989; 63:
625-627. PMID: 2919567
112. Wiener-Kronish JP, Matthay MA, Callen PW, et al. Relationship of pleural effusions to pulmonary hemodynamics in patients with
congestive heart failure. Am Rev Respir Dis 1985; 132: 1253-1256. PMID: 3907444
113. Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest 2004; 125: 669-682. PMID: 14769751
114. Giamouzis G, Sui X, Love TE, et al. A propensity-matched study of the association of cardiothoracic ratio with morbidity and mortality in
chronic heart failure. Am J Cardiol 2008; 101: 343-347. PMID:18237597
115. Daimon M, Watanabe H, Abe Y, et al. JAMP Study Investigators. Normal values of echocardiographic parameters in relation to age in a
healthy Japanese population: the JAMP study. Circ J 2008; 72: 1859-1866. PMID: 18827372
116. Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update
from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr
2015; 28: 1-39.e14. PMID: 25559473
117. Shimizu G, Hirota Y, Kita Y, et al. Left ventricular midwall mechanics in systemic arterial hypertension. Myocardial function is depressed
in pressure-overload hypertrophy. Circulation 1991; 83:1676-1684. PMID: 1827056
118. Voigt JU, Pedrizzetti G, Lysyansky P, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus
document of the EACVI/ASE/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr 2015; 28: 183-193.
PMID:25623220
119. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical utility of Doppler echocardiography and tissue Doppler imaging in the estimation
of left ventricular filling pressures: A comparative simultaneous Doppler-catheterization study. Circulation 2000; 102: 1788-1794.
PMID: 11023933
120. Geske JB, Sorajja P, Nishimura RA, et al. Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with
hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization. Circulation 2007; 116:
2702- 2708. PMID: 18025528
121. Pritchett AM, Mahoney DW, Jacobsen SJ, et al. Diastolic dysfunction and left atrial volume: a population-based study. J Am Coll Cardiol
2005; 45: 87-92. PMID: 15629380
122. Nagueh SF, Smiseth OA, Appleton CP, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by
Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.
Eur Heart J Cardiovasc Imaging 2016; 17: 1321-1360. PMID: 27422899
123. Andersen OS, Smiseth OA, Dokainish H, et al. Estimating Left Ventricular Filling Pressure by Echocardiography. J Am Coll Cardiol
2017; 69: 1937-1948. PMID: 28408024
124. Donal E, Lund LH, Oger E, et al. KaRen investigators. Value of exercise echocardiography in heart failure with preserved ejection fraction:
a substudy from the KaRen study. Eur Heart J Cardiovasc Imaging 2016; 17: 106-113. PMID: 26082167
125. Picano E, Pellikka PA. Ultrasound of extravascular lung water: a new standard for pulmonary congestion. Eur Heart J 2016; 37: 2097-
2104. PMID: 27174289
126. Karamitsos TD, Francis JM, Myerson S, et al. The role of cardiovascular magnetic resonance imaging in heart failure. J Am Coll Cardiol
2009; 54: 1407-1424. PMID: 19796734
127. 日本循環器学会．肥大型心筋症の診療に関するガイドライン（2012年改訂版）．
128. 日本循環器学会．循環器病の診断と治療に関するガイドライン2011．拡張型心筋症ならびに関連する二次性心筋症の診療に関するガイドライ
129. Babu-Narayan SV, Giannakoulas G, Valente AM, et al. Imaging of congenital heart disease in adults. Eur Heart J 2016; 37: 1182-1195.
PMID: 26424866
130. Karamitsos TD, Neubauer S. Cardiovascular magnetic resonance in heart failure. Curr Cardiol Rep 2011; 13: 210-219. PMID: 21360113
131. 日本循環器学会．循環器病ガイドラインシリーズ2016年度版．心臓サルコイドーシスの診療ガイドライン．
132. Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic
cardiomyopathies. Eur Heart J 2005; 26: 1461-1474. PMID: 15831557
133. Syed IS, Glockner JF, Feng D, et al. Role of cardiac magnetic resonance imaging in the detection of cardiac amyloidosis. JACC
Cardiovasc Imaging 2010; 3: 155-164. PMID: 20159642
134. Moon JC, Messroghli DR, Kellman P, et al. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular
Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn
Reson 2013; 15: 92-92. PMID: 24124732
135. Ghostine S, Caussin C, Habis M, et al. Non-invasive diagnosis of ischaemic heart failure using 64-slice computed tomography. Eur
Heart J 2008; 29: 2133-2140. PMID: 18385120
136. 日本循環器学会．慢性虚血性心疾患の診断と病態把握のための検査法の選択基準に関するガイドライン（2010年改訂版）．
137. 日本循環器学会．循環器病の診断と治療に関するガイドライン．心臓核医学検査ガイドライン．Circ J 2005; 69 suppl IV: 1125-
1202.
138. Bonow RO, Maurer G, Lee KL, et al. STICH Trial Investigators.Myocardial viability and survival in ischemic left ventricular dysfunction.
N Engl J Med 2011; 364: 1617-1625. PMID: 21463153
139. Shojaeifard M, Ghaedian T, Yaghoobi N, et al. Comparison of Gated SPECT Myocardial Perfusion Imaging with Echocardiography for the
Measurement of Left Ventricular Volumes and Ejection Fraction in Patients With Severe Heart Failure. Res Cardiovasc Med 2016; 5:
e29005. PMID: 26889455
140. Imamura Y, Ando H, Mitsuoka W, et al. Iodine-123 metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity
in congestive heart failure independent of underlying cause. J Am Coll Cardiol 1995; 26: 1594-1599. PMID: 7594091
141. Schofer J, Spielmann R, Schuchert A, et al. Iodine-123 meta-iodobenzylguanidine scintigraphy: a noninvasive method to demonstrate
myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1988; 12:
1252-1258. PMID: 3170968
142. Matsuo S, Nakamura Y, Tsutamoto T, et al. Impairments of myocardial sympathetic activity may reflect the progression of myocardial
damage or dysfunction in hypertrophic cardiomyopathy. J Nucl Cardiol2002; 9: 407-412. PMID: 12161717
143. Hongo M, Urushibata K, Kai R, et al. Iodine-123 metaiodobenzylguanidine scintigraphic analysis of myocardial sympathetic innervation
in patients with AL (primary) amyloidosis. Am Heart J 2002;144: 122-129. PMID: 12094198
144. Tsutsui H, Ando S, Kubota T, et al. Abnormalities of cardiac sympathetic neuronal and left ventricular function in chronic mitral
regurgitation: assessment by iodine-123 metaiodobenzylguanidine scintigraphy. Am J Card Imaging 1996; 10: 14-22. PMID: 8680129
145. Tamaki N, Yoshinaga K. Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology. J Nucl Cardiol 2011; 18: 135-143. PMID:
146. Kasama S, Toyama T, Kurabayashi M. Usefulness of Cardiac Sympathetic Nerve Imaging Using (123)Iodine-Metaiodobenzylguanidine
Scintigraphy for Predicting Sudden Cardiac Death in Patients With Heart Failure. Int Heart J 2016; 57: 140-144. PMID: 26973278
147. Yamazaki J, Muto H, Kabano T, et al. Evaluation of beta-blocker therapy in patients with dilated cardiomyopathy--Clinical meaning of
iodine 123-metaiodobenzylguanidine myocardial single-photon emission computed tomography. Am Heart J 2001; 141: 645-652. PMID:
148. Kasama S, Toyama T, Kumakura H, et al. Spironolactone improves cardiac sympathetic nerve activity and symptoms in patients with
congestive heart failure. J Nucl Med 2002; 43: 1279-1285. PMID: 12368364
149. Takeishi Y, Atsumi H, Fujiwara S, et al. ACE inhibition reduces cardiac iodine-123-MIBG release in heart failure. J Nucl Med 1997; 38:
1085-1089. PMID: 9225795
150. Maurer MS. Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology. Am J Med 2015; 128:
1275-1280. PMID: 26091765
151. Høilund-Carlsen PF, Lauritzen SL, Marving J, et al. The reliability of measuring left ventricular ejection fraction by radionuclide
cardiography: evaluation by the method of variance components. Br Heart J 1988; 59: 653-662. PMID: 3395524
152. Sakata K, Yoshino H, Kurihara H, et al. Prognostic significance of persistent right ventricular dysfunction as assessed by radionuclide
angiocardiography in patients with inferior wall acute myocardial infarction. Am J Cardiol 2000; 85: 939-944. PMID: 10760330
153. Le Guludec D, Gauthier H, Porcher R, et al. Prognostic value of radionuclide angiography in patients with right ventricular arrhythmias.
Circulation 2001; 103: 1972-1976. PMID: 11306526
154. Beanlands RS, Ruddy TD, deKemp RA, et al. PARR Investigators. Positron emission tomography and recovery following revascularization
(PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J
Am Coll Cardiol 2002; 40: 1735-1743. PMID: 12446055
155. Schinkel AF, Bax JJ, Poldermans D, et al. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 2007; 32: 375-
410. PMID: 17560992
156. D’Egidio G, Nichol G, Williams KA, et al. PARR-2 Investigators. Increasing benefit from revascularization is associated with increasing
amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging 2009; 2: 1060-1068. PMID: 19761983
157. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and
metaanalysis including the Ontario experience. J Nucl Med 2012; 53: 241- 248. PMID: 22228794
158. Shah MR, Hasselblad V, Stevenson LW, et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of
randomized clinical trials. JAMA 2005; 294: 1664-1670. PMID: 16204666
159. Binanay C, Califf RM, Hasselblad V, et al. ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive
heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005; 294: 1625-1633. PMID: 16204662
160. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of
the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:
1810-1852. PMID: 23741057
161. Abraham WT, Adamson PB, Bourge RC, et al. CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring
in chronic heart failure: a randomised controlled trial. Lancet 2011;377: 658-666. PMID: 21315441
162. Patel MR, Bailey SR, Bonow RO, et al. ACCF/SCAI/AATS/AHA/ASE/ASNC/HFSA/HRS/SCCM/SCCT/SCMR/STS 2012 appropriate
use criteria for diagnostic catheterization: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task
Force, Society for Cardiovascular Angiography and Interventions, American Association for Thoracic Surgery, American Heart Association,
American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm
Society, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic
Resonance, and Society of Thoracic Surgeons. J Am Coll Cardiol 2012;59: 1995-2027. PMID: 22578925
163. Authors/Task Force members. Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The
Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-
Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular
Interventions (EAPCI). Eur Heart J 2014; 35: 2541-2619. PMID: 25173339
164. Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task
Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013; 34: 2949-3003.
PMID:23996286
165. Roffi M, Patrono C, Collet JP, et al. Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment
Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients
presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting
without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37: 267-315. PMID: 26320110
166. Jolicoeur EM, Dunning A, Castelvecchio S, et al. Importance of angina in patients with coronary disease, heart failure, and left ventricular
systolic dysfunction: insights from STICH. J Am Coll Cardiol 2015;66: 2092-2100. PMID: 26541919
167. Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: a report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011; 124: e652-e735.
PMID: 22064599
168. Patel MR, Dehmer GJ, Hirshfeld JW, et al. ACCF/SCAI/STS/AATS/ AHA/ASNC 2009 Appropriateness Criteria for Coronary
Revascularization: A Report of the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for
Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart
Association, and the American Society of Nuclear Cardiology: Endorsed by the American Society of Echocardiography, the Heart Failure
Society of America, and the Society of Cardiovascular Computed Tomography. Circulation 2009; 119: 1330-1352. PMID: 19131581
169. Velazquez EJ, Lee KL, Deja MA, et al. STICH Investigators. Coronary- artery bypass surgery in patients with left ventricular dysfunction.
N Engl J Med 2011; 364: 1607-1616. PMID: 21463150
170. Cooper LT, Baughman KL, Feldman AM, et al. American Heart Association.The role of endomyocardial biopsy in the management of
cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the
European Society of Cardiology. Circulation 2007; 116: 2216-2233. PMID: 17959655
171. Mancini DM, Eisen H, Kussmaul W, et al. Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in
ambulatory patients with heart failure. Circulation 1991; 83: 778-786.PMID: 1999029
172. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for
Noncardiac Surgery: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery):
Developed in Collaboration With the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart
Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for
Vascular Medicine and Biology, and Society for Vascular Surgery. Circulation 2007; 116: 1971-1996. PMID: 17901356
173. Sasayama S, Asanoi H, Ishizaka S, et al. Evaluation of functional capacity of patients with congestive heart failure. In : Yasuda H,
Kawaguchi H, editors. New aspects in the treatment of failing heart syndrome. Springer-Verlag, 1992: 113-117.
174. 難病情報センター．特発性拡張型心筋症（指定難病５７）．http://www.nanbyou.or.jp/entry/3986
175. Goldman L, Hashimoto B, Cook EF, et al. Comparative reproducibility and validity of systems for assessing cardiovascular functional
class: advantages of a new specific activity scale. Circulation 1981; 64: 1227-1234. PMID: 7296795
176. Enright PL, Sherrill DL. Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 1998; 158: 1384-1387.
PMID: 9817683
177. 大西洋三，佐藤秀幸，是恒之宏，他．6分間歩行試験の正常値の 分布とその規定因子に関する検討．Jpn Circ J 1998; 61 (Suppl III):
856.
178. Bittner V, Weiner DH, Yusuf S, et al. SOLVD Investigators. Prediction of mortality and morbidity with a 6-minute walk test in patients
with left ventricular dysfunction. JAMA 1993; 270: 1702-1707. PMID: 8411500
179. Forman DE, Fleg JL, Kitzman DW, et al. 6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in
ambulatory outpatients with systolic heart failure. J Am Coll Cardiol2012; 60: 2653-2661. PMID: 23177293
180. Passantino A, Lagioia R, Mastropasqua F, et al. Short-term change in distance walked in 6 min is an indicator of outcome in patients with
chronic heart failure in clinical practice. J Am Coll Cardiol 2006; 48:99-105. PMID: 16814655
181. Cheetham C, Taylor R, Burke V, et al. The 6-minute walk test does not reliably detect changes in functional capacity of patients awaiting
cardiac transplantation. J Heart Lung Transplant 2005; 24: 848-853.PMID: 15982612
182. Wasserman K, Hansen JE, Sue D. Physiology of Exercise. In: Principles of Exercise Testing and Interpretation. Lea & Febiger, 1994.
183. Nakanishi M, Takaki H, Kumasaka R, et al. Targeting of high peak respiratory exchange ratio is safe and enhances the prognostic power
of peak oxygen uptake for heart failure patients. Circ J 2014; 78:2268-2275. PMID: 25056425
184. Koike A, Koyama Y, Itoh H, et al. Prognostic significance of cardiopulmonary exercise testing for 10-year survival in patients with mild
to moderate heart failure. Jpn Circ J 2000; 64: 915-920. PMID:11194282
185. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory
patients referred for cardiac transplant evaluation. Circulation1997; 95: 2660-2667. PMID: 9193435
186. Mudge GH, Goldstein S, Addonizio LJ, et al. 24th Bethesda conference: Cardiac transplantation. Task Force 3: Recipient
guidelines/prioritization. J Am Coll Cardiol 1993; 22: 21-31. PMID: 8509544
187. Fletcher GF, Ades PA, Kligfield P, et al. American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the
Council on Clinical Cardiology, Council on Nutrition, Physical Activity and Metabolism, Council on Cardiovascular and Stroke Nursing,
and Council on Epidemiology and Prevention. Exercise standards for testing and training: a scientific statement from the American
Heart Association. Circulation 2013; 128: 873-934. PMID: 23877260
188. Matsumura N, Nishijima H, Kojima S, et al. Determination of anaerobic threshold for assessment of functional state in patients with
chronic heart failure. Circulation 1983; 68: 360-367. PMID: 6222847
189. Stelken AM, Younis LT, Jennison SH, et al. Prognostic value of cardiopulmonary exercise testing using percent achieved of predicted
peak oxygen uptake for patients with ischemic and dilated cardiomyopathy. J Am Coll Cardiol 1996; 27: 345-352. PMID: 8557904
190. 日本循環器学会．心疾患患者の学校、職域、スポーツにおける運動許容条件に関するガイドライン（2008年改訂版）．
191. 日本循環器学会．心血管疾患におけるリハビリテーションに関するガイドライン（2012年改訂版）．
192. Arena R, Myers J, Aslam SS, et al. Peak VO2 and VE/VCO2 slope in patients with heart failure: a prognostic comparison. Am Heart J
2004; 147: 354-360. PMID: 14760336
193. Kostis JB, Davis BR, Cutler J, et al. SHEP Cooperative Research Group. Prevention of heart failure by antihypertensive drug treatment
in older persons with isolated systolic hypertension. JAMA 1997;278: 212-216. PMID: 9218667
194. Beckett NS, Peters R, Fletcher AE, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl
J Med 2008; 358: 1887-1898. PMID: 18378519
195. Sciarretta S, Palano F, Tocci G, et al. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network
meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med 2011; 171: 384-394.
PMID:21059964
196. Wright JT, Williamson JD, Whelton PK, et al. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure
Control. N Engl J Med 2015; 373: 2103-2116. PMID: 26551272
197. 日本高血圧学会．高血圧治療ガイドライン2014．ライフサイエンス出版 2014.
198. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients
randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997. PMID: 12479763
199. Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Diuretic versus alpha-blocker
as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack
Trial (ALLHAT). Hypertension 2003; 42: 239-246. PMID: 12925554
200. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic
dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581-588. PMID: 16905022
急性･慢性心不全診療ガイドライン（2017年改訂版）
Guidelines for Diagnosis and Treatment of Acute and Chronic Heart Failure
（JCS 2017/JHFS 2017）